deferoxamine has been researched along with Arrhythmias, Cardiac in 17 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Arrhythmias, Cardiac: Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
Excerpt | Relevance | Reference |
---|---|---|
"We examined the efficacy of long-term subcutaneous deferoxamine therapy in the prevention of iron-related cardiac disease in patients with thalassemia major who began treatment after the age of 10 years." | 7.67 | Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. ( Colan, S; Freedman, MH; Nathan, DG; Olivieri, N; Propper, R; Rose, V; Sallan, D; Wolfe, L, 1985) |
"Reversal of arrhythmia to sinus rhythm was noted in all patients." | 5.56 | Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020) |
"The incidence of cardiomyopathy was monitored in a 6-year follow-up study involving 56 transfused thalassemia patients treated with deferoxamine (DFO), deferiprone (L1) or their combination." | 3.73 | Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2006) |
"In patients with thalassemia major (TM) who are non-compliant with long-term deferoxamine (DFO) chelation, survival is limited mainly because of cardiac complications of transfusional siderosis." | 3.72 | Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. ( Berant, M; Hershko, C; Miskin, H; Tamary, H; Yaniv, I, 2003) |
"We examined the efficacy of long-term subcutaneous deferoxamine therapy in the prevention of iron-related cardiac disease in patients with thalassemia major who began treatment after the age of 10 years." | 3.67 | Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. ( Colan, S; Freedman, MH; Nathan, DG; Olivieri, N; Propper, R; Rose, V; Sallan, D; Wolfe, L, 1985) |
"Reversal of arrhythmia to sinus rhythm was noted in all patients." | 1.56 | Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020) |
"Juvenile hemochromatosis is a rare genetic disorder that causes iron overload." | 1.31 | Juvenile hemochromatosis associated with B-thalassemia treated by phlebotomy and recombinant human erythropoietin. ( Brunello, F; Camaschella, C; De Gobbi, M; Mazza, U; Paccotti, P; Pasquero, P, 2000) |
"Severe arrhythmias were encountered in two of eight studies with 40 micrograms/ml iron and in two of seven studies with 80 micrograms/ml iron, but they were not found in any of the 29 control studies (p less than 0." | 1.28 | Effect of iron loading on transmembrane potential, contraction, and automaticity of rat ventricular muscle cells in culture. ( Athias, P; Grynberg, A; Hershko, C; Link, G; Pinson, A, 1989) |
"Severe congestive cardiac failure developed in a few weeks in a 44 year old man who had undergone porto-caval anastamosis for post-hepatitis cirrhosis one year previously and then treated for anaemia by repeated blood transfusion and chronic daily oral iron therapy." | 1.27 | [Adiastole caused by a secondary cardiac hemochromatosis. Successful treatment with an iron chelating agent]. ( Azancot, I; Baudouy, P; Lombrail, P; Martin, E; Piekarski, A; Slama, R, 1983) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 10 (58.82) | 18.7374 |
1990's | 1 (5.88) | 18.2507 |
2000's | 4 (23.53) | 29.6817 |
2010's | 1 (5.88) | 24.3611 |
2020's | 1 (5.88) | 2.80 |
Authors | Studies |
---|---|
Chuang, TY | 1 |
Li, JP | 1 |
Weng, TF | 1 |
Wu, KH | 1 |
Chao, YH | 1 |
Origa, R | 1 |
Danjou, F | 1 |
Cossa, S | 1 |
Matta, G | 1 |
Bina, P | 1 |
Dessì, C | 1 |
Defraia, E | 1 |
Foschini, ML | 1 |
Leoni, G | 1 |
Morittu, M | 1 |
Galanello, R | 1 |
Miskin, H | 1 |
Yaniv, I | 1 |
Berant, M | 1 |
Hershko, C | 2 |
Tamary, H | 1 |
Borgna-Pignatti, C | 1 |
Rugolotto, S | 1 |
De Stefano, P | 1 |
Zhao, H | 1 |
Cappellini, MD | 1 |
Del Vecchio, GC | 1 |
Romeo, MA | 1 |
Forni, GL | 1 |
Gamberini, MR | 1 |
Ghilardi, R | 1 |
Piga, A | 1 |
Cnaan, A | 1 |
Kolnagou, A | 1 |
Economides, C | 1 |
Eracleous, E | 1 |
Kontoghiorghes, GJ | 1 |
Baudouy, P | 1 |
Lombrail, P | 1 |
Azancot, I | 1 |
Piekarski, A | 1 |
Martin, E | 1 |
Slama, R | 1 |
Euler, DE | 1 |
De Gobbi, M | 1 |
Pasquero, P | 1 |
Brunello, F | 1 |
Paccotti, P | 1 |
Mazza, U | 1 |
Camaschella, C | 1 |
Strohmeyer, G | 1 |
Kaye, SB | 1 |
Owen, M | 1 |
Young, N | 1 |
Henry, W | 1 |
Nienhuis, AW | 1 |
Link, G | 1 |
Athias, P | 1 |
Grynberg, A | 1 |
Pinson, A | 1 |
Bernier, M | 1 |
Hearse, DJ | 1 |
Manning, AS | 1 |
Bolli, R | 1 |
Patel, BS | 1 |
Zhu, WX | 1 |
O'Neill, PG | 1 |
Hartley, CJ | 1 |
Charlat, ML | 1 |
Roberts, R | 1 |
Giardina, PJ | 1 |
Ehlers, KH | 1 |
Engle, MA | 1 |
Grady, RW | 1 |
Hilgartner, MW | 1 |
Festa, RS | 1 |
Wolfe, L | 1 |
Olivieri, N | 1 |
Sallan, D | 1 |
Colan, S | 1 |
Rose, V | 1 |
Propper, R | 1 |
Freedman, MH | 1 |
Nathan, DG | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
A Pilot Study of 5-Azacytidine and Oral Sodium Phenylbutyrate in Severe Thalassemia[NCT00005934] | Phase 2 | 24 participants | Interventional | 2000-06-30 | Completed | ||
Effect of Hydroxyurea on the Level of Ineffective Erythropoiesis, Transfusion Requirement, and Fetal Hemoglobin Synthesis in Patients With Beta-Thalassemia-Intermedia[NCT00001958] | Phase 2 | 100 participants | Interventional | 1999-12-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
2 reviews available for deferoxamine and Arrhythmias, Cardiac
Article | Year |
---|---|
[Iron storage disorders].
Topics: Arrhythmias, Cardiac; Bloodletting; Deferoxamine; Diabetes Complications; Ferritins; Follicle Stimul | 1978 |
Modern management of thalassemia.
Topics: Adolescent; Arrhythmias, Cardiac; Ascorbic Acid; Blood Transfusion; Child; Cholelithiasis; Deferoxam | 1985 |
15 other studies available for deferoxamine and Arrhythmias, Cardiac
Article | Year |
---|---|
Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
Topics: Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Deferiprone; Deferoxamine; Drug Evaluati | 2020 |
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Defer | 2013 |
Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Catheterization, Central Venous; Chelation Therapy; Deferox | 2003 |
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
Topics: Adult; Age Factors; Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Cohort Studies; Defe | 2004 |
Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Cardiomyopathies; Chelation Therapy; Combined Mod | 2006 |
[Adiastole caused by a secondary cardiac hemochromatosis. Successful treatment with an iron chelating agent].
Topics: Adult; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Deferoxamine; Diastole; Echocardiography; Elec | 1983 |
Role of oxygen-derived free radicals in canine reperfusion arrhythmias.
Topics: Animals; Antioxidants; Arrhythmias, Cardiac; Blood Pressure; Catalase; Coronary Circulation; Coronar | 1995 |
Juvenile hemochromatosis associated with B-thalassemia treated by phlebotomy and recombinant human erythropoietin.
Topics: Adrenal Cortex Hormones; Adrenal Insufficiency; Adult; Arrhythmias, Cardiac; beta-Thalassemia; Chela | 2000 |
Cardiac arrhythmias in thalassaemia major: evaluation of chelation treatment using ambulatory monitoring.
Topics: Adolescent; Adult; Ambulatory Care; Arrhythmias, Cardiac; Child; Deferoxamine; Humans; Monitoring, P | 1978 |
Treatment of primary hemochromatosis with deferoxamine.
Topics: Adult; Arrhythmias, Cardiac; Deferoxamine; Female; Heart Failure; Hemochromatosis; Humans; Male; Ped | 1979 |
Effect of iron loading on transmembrane potential, contraction, and automaticity of rat ventricular muscle cells in culture.
Topics: Animals; Arrhythmias, Cardiac; Cells, Cultured; Deferoxamine; Heart; Iron; L-Lactate Dehydrogenase; | 1989 |
Reperfusion-induced arrhythmias and oxygen-derived free radicals. Studies with "anti-free radical" interventions and a free radical-generating system in the isolated perfused rat heart.
Topics: Animals; Arrhythmias, Cardiac; Catalase; Coronary Circulation; Coronary Disease; Deferoxamine; Free | 1986 |
The iron chelator desferrioxamine attenuates postischemic ventricular dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Coronary Circulation; Coronary Disease; Coronary Vessels; Deferoxamin | 1987 |
The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Child; Child, Preschool; Deferoxamine; Echocardiography; El | 1985 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |